Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus-Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

Styczynski, J.; Gil, L.; Tridello, G.; Ljungman, P.; Donnelly, P.; Velden, W. van der; ... ; Infect Dis Working Party European (2013)

Article / Letter to editor

• Epstein-Barr virus
• post-transplant lymphoproliferative disorder
• hematopoietic stem cell transplantation
• risk factors
• prognostic model

• All authors: Styczynski, J.; Gil, L.; Tridello, G.; Ljungman, P.; Donnelly, P.; Velden, W. van der; Omar, H.; Martino, R.; Halkes, C.; Faraci, M.; Theunissen, K.; Kalwak, K.; Hubacek, P.; Sica, S.; Nozzoli, C.; Fagioli, F.; Matthes, S.; Diaz, M.A.; Migliavacca, M.; Balduzzi, A.; Tomaszewska, A.; Camara, R. de la; Biezen, A. van; Hoek, J.; Iacobelli, S.; Einsele, H.; Cesaro, S.; Infect Dis Working Party European
• Date: 2013-09-15
• Journal: Clinical Infectious Diseases
• Volume: 57
• Issue: 6
• Pages: 794 - 802
• DOI: doi:10.1093/cid/cit391